INCY Technical Analysis
As of date:4/16/2021
INCY stock price:82.68
INCY 50 DMA:81.44
INCY 200 DMA:89.09
INCY MACD (200-50):7.65
INCY RSI:53.95
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)53.95
Extremely
Oversold

Also see:
INCY Market Cap History
INCY Shares Outstanding History
INCY YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes
Get Free SEC filing alerts for INCY:
INCY SEC Filing Email Alerts ServiceExternal link

Notable Two Hundred Day Moving Average Cross - APTO
1 hour, 16 minutes ago


Royal Gold (RGLD) Shares Cross Above 200 DMA
1 hour, 32 minutes ago


Itau Unibanco Holding (ITUB) Shares Cross Above 200 DMA
1 hour, 33 minutes ago


PAGS Makes Notable Cross Below Critical Moving Average
1 hour, 35 minutes ago


AQB Crosses Below Key Moving Average Level
4 hours, 17 minutes ago


Blueprint Medicines Breaks Below 200-Day Moving Average - Notable for BPMC
4 hours, 17 minutes ago


AQB Crosses Below Key Moving Average Level
4 hours, 17 minutes ago


CRMD Makes Notable Cross Below Critical Moving Average
4 hours, 21 minutes ago


PCRX Crosses Below Key Moving Average Level
4 hours, 21 minutes ago


MTA Makes Bullish Cross Above Critical Moving Average
4 hours, 26 minutes ago


Bullish Two Hundred Day Moving Average Cross - SNN
4 hours, 26 minutes ago


NovaGold Resources (NG) Shares Cross Above 200 DMA
4 hours, 27 minutes ago


Equity Commonwealth Breaks Above 200-Day Moving Average - Bullish for EQC
4 hours, 27 minutes ago


Cascades Breaks Above 200-Day Moving Average - Bullish for CAS.CA
7 hours, 12 minutes ago


Notable Two Hundred Day Moving Average Cross - SFIX
Thursday, April 15, 5:01 PM


More Technical Analysis News

INCY Technical AnalysisINCY RSI
Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of adults with intermediate or high-risk myelofibrosis, for the treatment of adults with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. Co. has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia.

When researching a stock like Incyte, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from INCY Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for INCY stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
INCY DMAINCY MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Incyte (INCY) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

IQV Technical Analysis
ISRG Technical Analysis
JNJ Technical Analysis
LH Technical Analysis
LLY Technical Analysis
MCK Technical Analysis
MDT Technical Analysis
MMM Technical Analysis
MRK Technical Analysis
MYL Technical Analysis
More Healthcare companies »

 

INCY Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2021, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.